Senior Management team


Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. Supported by strong equity base, we are a rapidly growing company with a dynamic portfolio of technology at the
cutting edge of molecular diagnostics.


Andrew Denver

Andrew Denver | Chairman

BSc (Hons), MBA, FAICD

Between 2002 and 2005, Andrew was President of Pall Asia, a subsidiary of Pall Corporation, with responsibility for all Pall Corporation activities in the Asia Pacific region.

Andrew joined Pall in 2002 with the acquisition by Pall Corporation of US Filter’s Filtration and Separations business, where he was President. Andrew was appointed President and Chief Operating Officer of the US Filter Filtration and Separations Group in February 1998 after US Filter acquired Memtec Limited. Prior to his position at US Filter, Andrew was President and Chief Operating Officer of Memtec Limited from 1987 to 1997, and prior to that, at Baxter Healthcare Corporation where he was employed for 12 years in a number of positions. Andrew’s last assignment at Baxter Healthcare Corporation was as President of the corporation’s US based Medical Devices Division.

Andrew is Chairman of Universal Biosensors Inc., and a non executive Director of Cochlear Ltd and Vaxxas Pty Ltd.

Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors. Andrew was appointed as a Director of SpeeDx Pty Ltd in 2009.

Andrew Jane

Andrew Jane | Non Executive Director

BSc (Hons), MSc

Andy is a Managing Director with Talu Ventures in Brisbane, Australia. Talu Ventures was founded in 2013 with a portfolio of investments formerly managed by CM Capital Investments. Andy joined CM Capital Investments in 2003 and spent 7 years as a Partner in the firm. Andy has more than 20 years of experience in the biomedical and IT industries. Following 4 years as a Project Manager at the CSIRO, Andy spent 5 years at AGEN Biomedical in various project management and business development roles. He joined Lake Technology, Sydney, in 1999, prior to its ASX listing, as Director of Business Development & Licensing. Lake Technology was later acquired by Dolby Labs in 2003. Andy is a current Director of Piedmont Animal Health, Piedmont Pharmaceuticals Inc., Osprey Medical Inc. (ASX: OSP), and SpeeDx.

Andy has a BSc Hons degree in Physics from the University of St Andrews in Scotland. He also has a Master of Science degree in Instrumentation from the University of Manchester. Andy has a Diploma of Financial Services (Financial Markets) from AFMA and a post-grad Certificate in Science Media & Journalism from the University of Technology in Sydney.

John E. Klopp

John E. Klopp | Non Executive Director


John Klopp was Worldwide Vice President, Business Development, for Johnson & Johnson’s Diabetes Care Franchise when he retired in 2009. During his sixteen year career with J&J, he established several partnerships with other companies, led the acquisition of two publicly traded companies, and led several successful patent legal actions. The acquisitions represented over 90% of the Diabetes Care Franchise sales in 2009.

Prior to Johnson & Johnson, he was Manager of Licenses and Acquisitions for DuPont Medical Products Department. During his 28 year career with DuPont, he held positions of increasing responsibility in New Venture Development, turnarounds, partnership and joint venture development, and M&A. After the formation of a joint venture with Applied BioTechnology (Inc.), he was elected to the Board of ABT.

In 2010, he was appointed to the Research and Development Committee of the Juvenile Diabetes Research Foundation. He received B.S. and M.S. degrees in Chemical Engineering from Oklahoma State University. John was appointed as a Director of SpeeDx Pty Ltd in 2010.

Bianca Ogden

Bianca Ogden | Non Executive Director

MBio PhD

After spending some time at Swiss pharmaceuticals company Novartis researching new HIV drugs (one of which has been approved and is in use today), Dr. Ogden went on to complete a PhD at University College London, investigating Kaposi’s sarcoma-associated herpesvirus. She then migrated to Australia and joined Johnson & Johnson as a molecular biologist, researching new drug targets in oncology.

Dr. Ogden embarked on a career change in 2003 and joined Platinum as an investment analyst. Her rich knowledge base in molecular biology and first-hand insights into the pharmaceutical and biotech industry give her a unique ability to delve deeply into the fundamentals of healthcare companies.
At Platinum Bianca manages the Platinum International Health Care Fund and leads the healthcare sector team.

Michael P. Rubin

Michael P. Rubin | Non Executive Director


Michael P. Rubin, M.D., Ph.D. is the founder and CEO of Northpond Ventures, a global venture capital fund dedicated to science and technology. Dr. Rubin’s active directorships include Mitra Biotech, DiCE Molecules, Inflammatix, Teckro, Candel, Sherlock Bio and Scipher Medicine. Dr. Rubin was previously co-founder and managing partner of Sands Capital Ventures, a global cross industry venture capital business, and affiliate of Sands Capital Management. Under Dr. Rubin’s leadership, SCV invested in dozens of leading startups, resulting in numerous successful businesses and exits, including but not limited to Complete Genomics (IPO), Dova (IPO), Quad Technologies (sale to Biotechne), Firefly Bioworks (sale to Abcam), and Agilis (Sale to PTC Therapeutics).

Dr. Rubin became a board-certified physician and surgeon, and completed his fellowship training at Harvard Medical School. Dr. Rubin has led multiple IRB-approved research groups, published numerous papers in refereed journals, written chapters in leading texts, conducted clinical trials on leading commercial molecules, received NIH funding for novel research, attained industry sponsored funding for original biotherapeutic investigations, presented studies at large international forums, and conducted basic science research in molecular genetics at Harvard’s Ocular Genetics Institute.

Dr. Rubin also holds an MBA from The University of Massachusetts Amherst, is a CFA charter holder, earned his medical doctorate at The University of Chicago, and holds a B.S. in Electrical Engineering from The UCLA Samueli School of Engineering, where he was the student graduation speaker. Dr. Rubin was appointed as a Director of SpeeDx Pty Ltd in 2019.


Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx employs a growing number of team members across our three offices in Sydney, Austin, and London. Follow us on LinkedIn for more information about SpeeDx careers.

Colin Denver

Colin Denver | Chief Executive Officer

Colin Denver is an experienced sales professional with nearly 20  years sales experience working in the Life Science and Diagnostic fields. He has experience in establishing new organisations having set up Bioline in Australia in 2004. Colin enjoyed continued growth while at Bioline with quarter on quarter growth achieved since inception. Colin went on to manage sales in Asia/Pacific for Meridian Bioscience (post Bioline acquisition) and drove consistent growth within the territory.

Colin started as Vice President of Sales and Marketing for SpeeDx, responsible for the promotion of all SpeeDx branded products as well as acquisition of new licensing and commercial agreements. He now holds the role of CEO, overseeing the expansion of SpeeDx as products are launched across Europe, United States and Australia/New Zealand. Colin holds a Bachelor of Science from Pepperdine University and a Post Graduate Diploma of Management from MGSM.

Elisa Mokany

Elisa Mokany | Chief Technology Officer


Elisa Mokany is a co-founder and the Chief Technology Officer at SpeeDx. In this role she leads the development of innovative diagnostic technologies and commercialization of infectious disease and antibiotic resistance tests. Elisa has over 20 years’ experience in medical research, she has worked for St Vincent’s hospital developing tests for the diagnosis of colorectal cancer and later at Johnson & Johnson Research (JJR) where she developed diagnostic tests for leukemia and was involved in the commercialisation of proprietary technology known as DzyNA PCR.

While at JJR, Elisa undertook studies towards her PhD, which involved co-invention of the novel nucleic acid technology, PlexZymes . Elisa is an inventor on 8 patents/patent applications involving nucleic acid analysis including the novel PlexPrime technology which has multiple applications in the in vitro diagnostic field. Elisa studied at the University of NSW, obtaining a BSc (Hons 1st Class) and later completed her PhD at JJR in conjunction with the School of Biotechnology and Biomolecular Science at the University of New South Wales.

Bhavin Raval

Bhavin Raval | Chief Financial Officer

Bhavin Raval has nearly 30 years of financial leadership experience across a broad range of industries including the last 18 years with Life Science and Biotech companies. He brings financial and executive leadership experience to SpeeDx in the areas of business operations, fiscal management and strategy, commercial partnering, M&A and integration activities, and private equity fundraising. His previous employers include Johnson & Johnson Research Pty Limited, Victor Chang Cardiac Research Institute and Calimmune Inc. He was a part of the senior management team of Calimmune Inc. that was acquired by CSL for a value of up to USD 416 M in August 2017. Bhavin is a Fellow Member of CPA Australia as well as a Fellow Member of the Governance Institute of Australia.

Alison Todd

Alison Todd | Chief Scientific Officer


Dr Alison Todd has extensive experience within the pharmaceutical industry where she developed several novel molecular analytical technologies which have been used for basic research, preclinical/clinical drug development and in vitro diagnostics. Her specific areas of scientific expertise include nucleic acid chemistry, particularly target amplification and catalytic DNA technologies, and the biology of cancer and viral diseases.

Prior to founding SpeeDx, Alison was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney. She was awarded the highly prestigious Johnson & Johnson Philip B. Hofmann Research Scientist Award which is a worldwide award for outstanding achievement in the field of research and development. In 2019, Alison was elected as a fellow of the Australian Academy of Technology and Engineering. Alison is an inventor on 18 patents/patent applications and her techniques have been used for molecular monitoring in nine international clinical trials for patients with HIV, leukaemia and various solid tumours. She has successfully championed multiple inventions through to product commercialization in various fields.

Alison studied at the University of Sydney, obtaining a BSc (Hons 1st Class), and graduating as Dux of the Physiology Department. Later she completed a PhD within the Faculty of Medicine at the same university. Alison maintains an active involvement within the academic community and holds an adjunct appointment as Senior Visiting Fellow at the University of New South Wales.

Contact SpeeDx for more information on Resistance Guided Therapy.